Injecting BRAVELLE^®

At Ferring, we understand that having to mix and administer your own medication may seem overwhelming, and increased stress and anxiety levels can potentially hinder your treatment. We want to make it as easy and stress-free as possible.

In a survey among members of RESOLVE, The National Infertility Association, patients who were prescribed multiple injection methods (needle and syringe plus pen) experienced higher levels of anxiety when handling, preparing, and injecting their medications.

When you use Ferring fertility products, injection via needle and syringe is the only method you need to learn so you can feel much more confident and relaxed as treatment proceeds.

BRAVELLE^® is approved for reconstitution with the Q•Cap™ needle-free vial adapter and both subcutaneous (SC) and intramuscular (IM) injection. Whether your doctor has prescribed an SC or IM injection method, we’ve developed easy-to-follow injection guides. Simply access the instructions below.

If you have any questions or concerns regarding your injections, don't hesitate to contact your health care provider.

BRAVELLE^® administered SC in conjunction with hCG is indicated for multiple follicular development (controlled ovarian stimulation) during ART cycles in patients who have previously received pituitary suppression. BRAVELLE^® administered SC or IM, in conjunction with hCG, is indicated for ovulation induction in patients who have previously received pituitary suppression.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe BRAVELLE^®. BRAVELLE^®, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (incidence 6.0%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. BRAVELLE^® is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; the presence of any cause of infertility other than anovulation; abnormal bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to urofollitropins, purified. BRAVELLE^® is contraindicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman. There are limited human data on the effects of BRAVELLE^® when administered during pregnancy.

Previous: BRAVELLE®

Next: BRAVELLE® FAQs